We are working on studies in several cancer types

Clinical Trials

We are proud of the clinical evidence, R&D achievements, our FDA’s breakthrough device designation for our pancreatic cancer test panel, and our history has Bluestar Genomics. Now, as a commercial-stage company, ClearNote Health continues to drive innovation in non-invasive cancer detection, with patient needs at the core of everything we pursue. ClearNote Health is currently conducting several clinical studies at multiple sites. Learn more about study design, patient criteria, and enrollment below.

The Vanguard Study

The Vanguard
Study will enroll up to 24,000 people to inform the design of a much larger RCT that will evaluate whether the benefits of using MCD tests to screen for cancer outweigh the harms, and whether they can detect cancer early in a way that reduces deaths.

SAFE-D

The aim
of the SAFE-D research study is to evaluate a novel blood test, the Avantect test, to detect clues or biomarkers for the presence of pancreatic cancer in people that have been newly diagnosed with type II diabetes.

Clinical Trials

The Vanguard Study

SAFE-D

Company

Solutions

Stay Informed